Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,727,438
  • Shares Outstanding, K 742,666
  • Annual Sales, $ 0 K
  • Annual Income, $ -221,320 K
  • EBIT $ -250 M
  • EBITDA $ -250 M
  • 60-Month Beta -0.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 49.80

Options Overview Details

View History
  • Implied Volatility 88.75% ( -1.17%)
  • Historical Volatility 178.04%
  • IV Percentile 20%
  • IV Rank 12.73%
  • IV High 201.90% on 05/28/24
  • IV Low 72.25% on 04/02/25
  • Put/Call Vol Ratio 0.12
  • Today's Volume 3,655
  • Volume Avg (30-Day) 13,248
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 131,363
  • Open Int (30-Day) 121,448

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.10
  • Number of Estimates 4
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.75 +9.75%
on 05/15/25
36.91 -35.33%
on 04/24/25
+0.82 (+3.56%)
since 04/16/25
3-Month
15.55 +53.50%
on 04/07/25
36.91 -35.33%
on 04/24/25
+2.50 (+11.70%)
since 02/14/25
52-Week
2.10 +1,036.67%
on 05/28/24
36.91 -35.33%
on 04/24/25
+19.36 (+429.27%)
since 05/16/24

Most Recent Stories

More News
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money

MSFT : 454.27 (+0.25%)
GOOGL : 166.19 (+1.36%)
NVDA : 135.40 (+0.42%)
GOOG : 167.43 (+1.23%)
SKM : 20.54 (+1.08%)
SMMT : 23.87 (+3.38%)
MRK : 76.06 (+1.68%)
APLD : 6.83 (+22.18%)
IONQ : 34.99 (+7.53%)
GD : 280.71 (+0.79%)
AMZN : 205.59 (+0.20%)
Can Summit Therapeutics Stock Double Your Money?

Summit Therapeutics (NASDAQ: SMMT) has more than just a potential blockbuster cancer drug in its portfolio. Ivonescimab could be one of the best drugs to ever hit the market. This has investors excited...

SMMT : 23.87 (+3.38%)
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil

Summit Therapeutics SMMT reported first-quarter 2025 loss per share of 9 cents, narrower than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago period, the company incurred a loss of...

MRK : 76.06 (+1.68%)
SMMT : 23.87 (+3.38%)
PFE : 22.83 (+1.02%)
This Soaring Stock Just Delivered More Good News. Time to Buy?

It's hard to find a biotech company that has performed better than Summit Therapeutics (NASDAQ: SMMT) in the past year. The stock is up by a whopping 512%, and it's no secret why.

SMMT : 23.87 (+3.38%)
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?

Merck MRK reported its first-quarter 2025 results last week, beating estimates for both earnings and sales. Adjusted earnings of $2.22 per share rose 12% year over year, excluding foreign exchange impact....

MRK : 76.06 (+1.68%)
SMMT : 23.87 (+3.38%)
MRNA : 24.86 (+5.12%)
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (NASDAQ: SMMT) and BioNTech...

SMMT : 23.87 (+3.38%)
AKESF : 10.6000 (+0.95%)
BNTX : 92.77 (+0.47%)
Why Summit Therapeutics Rocketed Double-Digits Today

Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET.

BGNE : 184.71 (+0.49%)
SMMT : 23.87 (+3.38%)
AKESF : 10.6000 (+0.95%)
This Company's Co-CEOs Just Bought More Shares. Should You?

Nobody has more information about a company than its insiders, especially its executive management team. That's why when one of them buys more shares, it sometimes gives individual investors insights into...

SMMT : 23.87 (+3.38%)
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX

Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.

SMMT : 23.87 (+3.38%)
RXRX : 4.56 (+7.29%)
PTN : 0.0941 (-44.65%)
3 Magnificent Stocks That Could Double or More by 2030

When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant...

VKTX : 28.43 (+3.76%)
CRSP : 38.77 (+6.77%)
SMMT : 23.87 (+3.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 25.10
2nd Resistance Point 24.52
1st Resistance Point 24.20
Last Price 23.87
1st Support Level 23.29
2nd Support Level 22.71
3rd Support Level 22.39

See More

52-Week High 36.91
Last Price 23.87
Fibonacci 61.8% 23.61
Fibonacci 50% 19.50
Fibonacci 38.2% 15.40
52-Week Low 2.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar